| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $6,058,522 | 7 | 100 |
| GOLDSTEIN DOV A MD | Chief Financial Officer | 0 | $0 | 1 | $531,828 | $-531,828 |
| RUBIN PAUL D | Chief Medical Officer | 0 | $0 | 5 | $1.3M | $-1.3M |
| Fortney Kristen | Chief Executive Officer | 0 | $0 | 1 | $4.22M | $-4.22M |
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Over the last 12 months, insiders at BioAge Labs, Inc. have bought $0 and sold $6.06M worth of BioAge Labs, Inc. stock.
On average, over the past 5 years, insiders at BioAge Labs, Inc. have bought $101,376 and sold $6.06M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,000 shares for transaction amount of $54,000 was made by Hemrajani Rekha (director) on 2024‑09‑27.
| 2026-03-02 | Sale | RUBIN PAUL D | Chief Medical Officer | 7,433 0.0189% | $20.30 | $150,890 | -6.00% | |
| 2026-02-02 | Sale | RUBIN PAUL D | Chief Medical Officer | 7,433 0.0193% | $18.75 | $139,369 | +1.39% | |
| 2026-01-13 | Sale | Fortney Kristen | Chief Executive Officer | 233,107 0.5693% | $18.12 | $4.22M | -2.59% | |
| 2026-01-13 | Sale | GOLDSTEIN DOV A MD | Chief Financial Officer | 27,000 0.0717% | $19.70 | $531,828 | -2.59% | |
| 2026-01-02 | Sale | RUBIN PAUL D | Chief Medical Officer | 7,433 – | $12.85 | $95,490 | +56.82% | |
| 2025-12-09 | Sale | RUBIN PAUL D | Chief Medical Officer | 18,000 0.0403% | $12.00 | $216,000 | +62.52% | |
| 2025-12-04 | Sale | RUBIN PAUL D | Chief Medical Officer | 68,897 0.1308% | $10.19 | $701,909 | +86.48% | |
| 2024-09-27 | Hemrajani Rekha | director | 3,000 0.0101% | $18.00 | $54,000 | -78.38% | ||
| 2024-09-27 | Barton Shane | Principal Accounting Officer | 2,632 0.0088% | $18.00 | $47,376 | -78.38% | ||
| 2017-08-15 | BRINER KURT W | director | 133,333 0.0186% | $0.75 | $100,000 | |||
| 2017-08-15 | Settino Mario | Chief Financial Officer | 20,000 0.0028% | $0.75 | $15,000 | |||
| 2017-08-15 | LAND RAYMOND J | director | 53,333 0.0075% | $0.75 | $40,000 | |||
| 2017-08-15 | Haller Heinz | director | 40,000 0.0056% | $0.75 | $30,000 | |||
| 2017-08-15 | Orecchioni Fabrice | Chief Operations Officer | 26,666 0.0037% | $0.75 | $20,000 | |||
| 2017-08-15 | Millis James | Chief Technology Officer | 13,333 0.0019% | $0.75 | $10,000 | |||
| 2017-08-15 | RICHSTONE ELLEN B | director | 13,333 0.0019% | $0.75 | $10,000 | |||
| 2017-08-09 | Settino Mario | Chief Financial Officer | 15,000 0.0015% | $0.53 | $8,024 | |||
| 2016-11-09 | Gosbee George Frederick John | director | 25,000 0.018% | $3.87 | $96,630 | |||
| 2016-11-08 | BRINER KURT W | director | 10,000 0.0072% | $3.84 | $38,415 | |||
| 2016-05-24 | BRINER KURT W | director | 1,000 0.0007% | $3.69 | $3,691 |
| Increased Positions | 67 | +78.82% | 7M | +33.08% |
| Decreased Positions | 32 | -37.65% | 5M | -22.48% |
| New Positions | 27 | New | 5M | New |
| Sold Out Positions | 9 | Sold Out | 2M | Sold Out |
| Total Postitions | 120 | +41.18% | 24M | +10.6% |